This Article Full Text Full Text (PDF) eLetters: Submit a response to this article Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services E-mail this article link to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Frank, T. S. Search for Related Content PubMed PubMed Citation Articles by Frank, T. S.

Hereditary Risk of Breast and Ovarian Carcinoma: The Role of the Oncologist

Myriad Genetic Laboratories, Salt Lake City, Utah, USA

Correspondence: Thomas S. Frank, M.D., Myriad Genetic Laboratories, 320 Wakara Way, Salt Lake City, Utah 84108, USA. Telephone: 801-584-3531; Fax: 801-584-3515; e-mail: tfrank{at}myriad.com

The American Society of Clinical Oncology has affirmed the role of clinical oncologists in identifying and managing patients with familial cancer risk. Inherited mutations in the genes BRCA1 and BRCA2 are responsible for the majority of hereditary breast and ovarian cancers, and these mutations also increase the risk of second cancers in women already diagnosed with breast malignancy. Understanding the likelihood of breast and ovarian cancer associated with mutations in BRCA1 and BRCA2 begins with consideration of the biological basis of hereditary cancer risk. Identifying patients with hereditary risk requires documentation of appropriate family history, and recent studies have characterized criteria for identifying women most likely to have inherited mutations in these genes. Options for women with inherited mutations in BRCA1 and BRCA2 include surveillance, chemoprevention and prophylactic surgery, which must be considered separately for the management of the risk of breast cancer and of ovarian cancer. Knowledge of the hallmarks of hereditary risk, options for medical intervention, possible results of BRCA1 and BRCA2 laboratory analysis and the psychological concerns of patients about hereditary risk evaluation enables oncologists and other health care providers to effectively counsel and manage women with hereditary risk of breast and ovarian cancer.

Key Words. Breast • Ovary • Cancer • BRCA1 • BRCA2 • Hereditary

This article has been cited by other articles:

				D. C. Allain Genetic Counseling and Testing for Common Hereditary Breast Cancer Syndromes: A Paper from the 2007 William Beaumont Hospital Symposium on Molecular Pathology J. Mol. Diagn., September 1, 2008; 10(5): 383 - 395. [Abstract] [Full Text] [PDF]

				J. Simard, M. Dumont, A.-M. Moisan, V. Gaborieau, H. Vezina, F. Durocher, J. Chiquette, M. Plante, D. Avard, P. Bessette, et al. Evaluation of BRCA1 and BRCA2 mutation prevalence, risk prediction models and a multistep testing approach in French-Canadian families with high risk of breast and ovarian cancer J. Med. Genet., February 1, 2007; 44(2): 107 - 121. [Abstract] [Full Text] [PDF]

				M. D. Schwartz, C. Lerman, B. Brogan, B. N. Peshkin, C. Hughes Halbert, T. DeMarco, W. Lawrence, D. Main, C. Finch, C. Magnant, et al. Impact of BRCA1/BRCA2 Counseling and Testing on Newly Diagnosed Breast Cancer Patients J. Clin. Oncol., May 15, 2004; 22(10): 1823 - 1829. [Abstract] [Full Text] [PDF]